Sasaki, Koji

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Kim, K., Maiti, A., Loghavi, S., Pourebrahim, R., Kadia, T. M., Rausch, C. R., Furudate, K., Daver, N. G., Alvarado, Y., Ohanian, M., et al. (2021) · Cancer

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 161

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Hochhaus, A., Réa, D., Boquimpani, C., Minami, Y., Cortes, J. E., Hughes, T. P., Apperley, J. F., Lomaia, E., Voloshin, S., Turkina, A., et al. (2023) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 148

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Montalban-Bravo, G., Kanagal-Shamanna, R., Benton, C. B., Class, C. A., Chien, K. S., Sasaki, K., Naqvi, K., Alvarado, Y., Kadia, T. M., Ravandi, F., et al. (2020) · Blood Advances

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 133

Impact of the variant allele frequency of ASXL1 , DNMT3A , JAK2 , TET2 , TP53 , and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

Sasaki, K., Kanagal‐Shamanna, R., Montalban‐Bravo, G., Assi, R., Jabbour, E., Ravandi, F., Kadia, T., Pierce, S., Takahashi, K., Nogueras Gonzalez, G., et al. (2020) · Cancer

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 101

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

Cortes, J. E., Sasaki, K., Kim, D.-W., Hughes, T. P., Etienne, G., Mauro, M. J., Hochhaus, A., Lang, F., Heinrich, M. C., Breccia, M., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 56

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia

Bidikian, A., Kantarjian, H., Jabbour, E., Short, N. J., Patel, K., Ravandi, F., Sasaki, K., & Issa, G. C. (2022) · Blood Cancer Journal

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 55

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Mauro, M. J., Hughes, T. P., Kim, D.-W., Rea, D., Cortes, J. E., Hochhaus, A., Sasaki, K., Breccia, M., Talpaz, M., Ottmann, O., et al. (2023) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 53

Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor

Bidikian, A., Jabbour, E., Issa, G. C., Short, N. J., Sasaki, K., & Kantarjian, H. (2023) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 32

Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results

Gener-Ricos, G., Haddad, F. G., Sasaki, K., Issa, G. C., Skinner, J., Masarova, L., Borthakur, G., Alvarado, Y., Garcia-Manero, G., Jabbour, E., et al. (2023) · Clinical Lymphoma Myeloma and Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 30

The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors

Jabbour, E. J., Sasaki, K., Haddad, F. G., Issa, G. C., Garcia‐Manero, G., Kadia, T. M., Jain, N., Yilmaz, M., DiNardo, C. D., Patel, K. P., et al. (2023) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 22

Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results

Cortes, J. E., Lang, F., Rea, D., Hochhaus, A., Breccia, M., Goh, Y. T., Heinrich, M. C., Hughes, T. P., Janssen, J. J. W. M., le Coutre, P., et al. (2025) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 16

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results

Hochhaus, A., Kim, D.-W., Cortes, J. E., Sasaki, K., Mauro, M. J., Hughes, T. P., Breccia, M., Talpaz, M., Minami, H., Goh, Y. T., et al. (2025) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 14

Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research

Kantarjian, H., Zhai, Y., Oehler, V. G., Jamy, O., Koller, P. B., Haddad, F. G., Sasaki, K., & Jabbour, E. J. (2025) · Cancer

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 10

The presence of additional cytogenetic abnormalities ( ACAs ) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemia

Haddad, F. G., Sasaki, K., Issa, G. C., Jabbour, E., & Kantarjian, H. (2024) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 4